New Technology May Mean Longer Lasting CGM Sensors

If you have ever used a continuous glucose monitoring (CGM) system to manage type 1 diabetes (T1D), you know that the glucose sensors typically only last a few days before they must be replaced. This can be an annoying yet necessary part of ensuring accurate results and effectively managing blood sugar levels. However, Senseonics recently received approval from the FDA on its Premarket Approval (PMA) application for a device containing a sensor that lasts up to three months before needing to be replaced.

The Eversense® CGM system is the only one to offer this continuous long-term monitoring. Rather than patients inserting the sensor themselves, it is implanted subcutaneously in the upper arm by a physician as an in-office procedure. This can help to alleviate the concern that individuals may have about doing it themselves or experiencing discomfort while wearing the sensor.

CGM systems can greatly improve diabetes management, but unfortunately, many people still are not taking advantage of this technology either because it is not available to them, they are concerned about the accuracy of the system, or they do not wear it as consistently as they should. Since this new system uses a sensor that lasts for up to three months, it eliminates the need to regularly change out sensors. Plus, the transmitter used to relay information is easily recharged without having to change sensors, and it works using Bluetooth technology. It also offers discreet on-body vibrations to give users alerts. CGM systems have been shown to decrease the risk of severe hypoglycemia and improve glucose control in individuals with T1D.

The Diabetes Research Connection (DRC) is interested to see how long-term sensors impact CGM use and management of T1D. The DRC is committed to supporting advancements in the treatment and prevention of T1D as well as improved quality of life for individuals living with the disease. That is why the organization provides valuable funding for early career scientists to conduct peer-reviewed, novel research studies for T1D. Check out current projects and learn how you can help by visiting

Related News

Research Findings May Provide Answers to Diabetes Complication of Peripheral Neuropathy

Learn More +
Genetics in T1D

DRC’s Take on, “The type 1 diabetes gene TYK2 regulates βcell development and its responses to interferon-α”

Learn More +

DRC Is Excited to Share This Breaking T1D News Announced Yesterday by the FDA

Learn More +